Insulins/Oral hypoglycemics

Question 1

This is the ONLY insulin that can be administered via IV:
A.  Lantus
B.  Novolog
C.  Humalog
D.  Humulin R

Answer 1

D. Humulin R

Question 2

This short acting insulin has a peak action of 2-4 hours and a duration of 6-8 hours:
A.  Lispro (Humalog)
B.  Lente
C.  Humulin R
D.  Glargine (Lantus)

Answer 2

C. Humulin R

Question 3

What characteristics are true about Glargine (Lantus)? (select all)
A. It can be mixed with other insulins
B. It is a long acting insulin
C. It has no pronounced peak time
D. It has a duration of 24 hours
E. Onset is 1-2 hours after administration

Answer 3

B. It is a long acting insulin
C. It has no pronounced peak time
D. It has a duration of 24 hours
E. Onset is 1-2 hours after administration

Question 4

The following are rapid or short acting insulins EXCEPT:
A.  Lispro (Humalog)
B.  Lente
C.  Aspart (NovoLog)
D.  Humulin R

Answer 4

B. Lente

Question 5

Which of the following can be used to treat hypoglycemia:
A.  Glucophage
B.  Glucotrol
C.  Glucagon
D.  Glimepiride

Answer 5

C. Glucagon

Question 6

Which oral medication is classified as a Biguanide and works primarily by reducing hepatic glucose production to lower fasting blood glucose levels:
A.  Glipizide (Glucotrol)
B.  Pioglitazone (Actone)
C.  Metformin (Glucophage)
D.  Exenatide (Byetta)

Answer 6

C. Metformin (Glucophage)

Question 7

Which of the following is administered by subcutaneous injection:  (select all)
A.  Pramlintide (Symlin)
B.  Nateglinide (Starlix)
C.  Exenatide (Byetta)
D.  Miglitol (Glyset)

Answer 7

A. Pramlintide (Symlin)

C. Exenatide (Byetta)

Question 8

This classification of oral hypoglycemics stimulates the beta cells to release insulin and increases the insulin sensitivity at receptor sites.
A.  Biguanides
B.  Sulfonylureas
C.  Nonsulfonylureas
D.  Incretin mimetics

Answer 8

B. Sulfonylureas

Question 9

This hypoglycemic medication is administered by injection and is only for use in type 2 diabetics.  Its stimulates release of insulin from the beta cells, decreases glucagon secretion, increases satiety and decreases gastric emptying. It may increase the risk for kidney problems and is contraindicated for patients with renal impairment.
A.  Humulin R
B.  Exenatide (Byetta)
C.  Pramlintide (Symlin)
D.  Lente

Answer 9

B. Exenatide (Byetta)

Question 10

This subcutaneous agent acts as an adjunct to insulin therapy.  It can be used in both type I and type II diabetes.  It carries a black box warning because of the potential to cause severe hypoglycemia within 3 hours of administration.
A.  Humulin R
B.  Exenatide (Byetta)
C.  Pramlintide (Symlin)
D.  Lente

Answer 10

C. Pramlintide (Symlin)